# TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)

> **NCT07720843** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Montefiore Medical Center** · enrollment: 50 (estimated)

## Conditions studied

- Relapse Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Talquetamab
- **DRUG:** Belantamab mafodotin
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT07720843
- **Lead sponsor:** Montefiore Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2030-03
- **Final completion:** 2032-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07720843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07720843, "TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07720843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*